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Background
Recently, we found that CD4+CD161+ T lymphocytes
showing transient nature of the Th17 phenotype are
present in the synovial fluid of patients with JIA, and
that their accumulation positively correlates with para-
meters of inflammation, supporting the hypothesis that
these cells may play a role in disease activity.
Aim
In the present study, we assessed the ability of etaner-
cept to influence the in vitro development of different T
cell subsets in JIA patients. In particular, we have evalu-
ated the ability of peripheral blood (PB) and synovial
fluid (SF) lymphocytes from patients followed in our
Unit, to proliferate and produce cytokines in response
to polyclonal (antiCD3/antiCD28) stimulation in pre-
sence or in absence of etanercept.
Methods
Lymphocytes from PB and SF have been cultured in the
presence of etanercept (5 µg/ml), and proliferative
responses were evaluated as thimidine uptake and % of
bromodeoxyuridine positive cells. Cell phenotype by
flow cytometry and cytokine production (% of producing
cells) in CD4+ cells were also assessed.
Results
We have initially studied 11 patients with oligoarticular or
polyarticular JIA who underwent therapeutic arthrocent-
esis, with concomitant venipuncture for routine blood
tests. Administration in culture of etanercept did not signif-
icantly affect the proliferative response to aCD3/aCD28
stimulation of both PB- and SF-derived total CD4+ lym-
phocytes, whereas the presence in culture of etanercept
increased the frequency of proliferating CD4+CD161+ lym-
phocytes. Accordingly, etanercept in vitro administration
increased the frequency of total IL-17-producing CD4+ T
cells, leaving the IFN-gamma-producing ones unaffected.
Conclusions
These in vitro preliminary results seem to indicate that
etanercept is able to increase the frequency of IL-17
producing cells by favouring their proliferation.
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